Dramatic response to alectinib in a lung cancer patient with a novel *VKORC1L1*-ALK fusion and an acquired ALK T1151K mutation

Viola W Zhu¹

Alexa B Schrock²

Thangavijayan Bosemani³

Bryan S Benn⁴

Siraj M Ali²

Sai-Hong Ignatius Ou¹

¹Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA;

²Clinical Development, Foundation Medicine, Inc., Cambridge, MA, USA;

³Department of Radiological Sciences, University of California, Irvine School of Medicine, Orange, CA, USA;

⁴Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA

Abstract: *ALK*-rearranged lung cancer defines a distinctive molecular cohort of patients whose outcomes are significantly improved by the availability of *ALK* inhibitors. Thus, it is imperative for clinicians to screen appropriate patients for this driver mutation with a molecular testing platform capable of capturing all *ALK* fusions. Here, we report a novel *VKORC1L1*-*ALK* fusion and an *ALK* T1151K resistance mutation detected in a lung cancer patient who had been on crizotinib for over 8 years. Alectinib induced a dramatic response in this patient demonstrating its clinical activity against T1151K. This case illustrates the importance of performing repeat biopsy to explore mechanism(s) of resistance when patients experience disease progression on an *ALK* inhibitor. The approach has a direct therapeutic impact particularly when an *ALK* resistance mutation is identified.

Keywords: *VKORC1L1*, T1151, fusion, resistance, crizotinib, lorlatinib

Introduction

In the US, there are now four approved *ALK* inhibitors for patients with metastatic *ALK*-rearranged lung cancer and many more at various development stages. Because of significant clinical benefits these *ALK* inhibitors provide, it is imperative for clinicians to screen appropriate patients for this driver mutation with a molecular testing platform capable of capturing all *ALK* fusions. For patients who progress on an *ALK* inhibitor, performing repeat biopsy to look for mechanism(s) of resistance is highly recommended. Identifying an *ALK* resistance mutation may guide selection of another *ALK* inhibitor with known activity against the specific mutation. Here, we report a novel *VKORC1L1*-*ALK* fusion with an acquired *ALK* T1151K resistance mutation detected in a patient who had disease progression after being on crizotinib for over 8 years. He had a dramatic response to alectinib illustrated in the following narrative indicating that T1151K confers sensitivity to alectinib.

Case presentation

A 54-year-old Caucasian man, former smoker of <5 pack years, originally underwent resection for locally advanced adenocarcinoma of the lung in April 2006 followed by adjuvant chemoradiation with weekly carboplatin/paclitaxel for focally positive margin. He was found to have metastatic disease in his pelvis in November 2008 for which he received palliative radiation. In October 2009, a computed tomography (CT) scan performed for cough showed multiple bilateral subcentimeter lung nodules and a large left pleural effusion. However, the patient had elected not to receive any treatment

Correspondence: Viola W Zhu
Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, 101 The City Drive South, Orange, CA 92868, USA
Tel +1 714 456 8105
Fax +1 714 456 6179
Email zhuvw@uci.edu

until February 2010 when he presented to our cancer center to discuss participation in clinical trial. The molecular profiling performed at the Massachusetts General Hospital revealed an *ALK* rearrangement, so he was enrolled in the PROFILE 1001 study (NCT00585195) in March 2010. He had a sustained partial response (PR, –27% by RECIST 1.1) to crizotinib at 250 mg twice daily confirmed by a contrast CT scan in October 2012. He declined further scans afterwards, and so he was switched to commercial supply of crizotinib in February 2013.

In April 2018, the patient developed dry cough while on crizotinib for which a contrast CT scan of the chest was performed that showed complete opacification of the left hemithorax (Figure 1). Restaging scans confirmed disease progression in both lungs, thoracic lymph nodes, pleura, and bone. He was immediately switched to alectinib at 600 mg twice daily while comprehensive genomic profiling (CGP) via Foundation Medicine, Inc. (Cambridge, MA, USA) was performed on a plasma-based liquid biopsy which subsequently identified a novel *VKORC1L1-ALK* fusion as well as an *ALK* T1151K resistance mutation. This CGP assay covers 62 genes to ×5,000 unique coverage and includes intron baiting for rearrangements of six genes (*ALK*, *EGFR*, *FGFR3*, *PDGFR-α*, *ROS1*, and *RET*). Alectinib was continued based on predicted efficacy of this *ALK* inhibitor against T1151K. A follow-up contrast CT scan of the chest 14 weeks later showed a dramatic response (–76% by RECIST 1.1) including resolution of a 2.9 cm left paravertebral mass at T1–2 level, decrease in size of the right pulmonary nodule from 1.8 to 1.1 cm, and significant improvement of the left lung aeration (Figure 1). Of note, prior to this follow-up scan, the patient underwent endobronchial cryosurgery for tissue extraction and spray cryotherapy of an endobronchial mass in order to prevent any significant pulmonary hemorrhage and for airway recanalization, but we did not obtain enough tissue for CGP. At the time of this manuscript preparation, the patient has been on alectinib for over 23 weeks with no reported symptoms. A written informed consent was obtained to have the case details published, and institutional approval was not required to publish this case report.

Discussion

We believe this is the first report of *VKORC1L1-ALK* fusion detected in a lung cancer patient. Ever since the discovery of the transforming *EML4-ALK* fusion gene by Soda and Rikova et al in 2007, various *ALK* fusion partners have been identified including *TFG*, *KIF5B*, *KCL1*, *PTPN3*, *STRN*, *HIP1*, *TPR*, *BIRC6*, *DCTN1*, *SQSTM1*, *SOC5*, *CLIP4*, *CLTC*, *PRKAR1A*, *PPM1B*, *EIF2AK3*, *CRIM1*, *GCC2*,

DYSF, *ITGAV*, *VIT*, *PLEKHA7*, and *CUX1*.^{1–19} A list of chronologically published fusion partners in *ALK*-rearranged lung cancer with references is summarized in Table 1. The *VKORC1L1* gene encodes an enzyme known as vitamin K 2,3-epoxide reductase, whose catalytic function is critical for the vitamin K cycle. The vitamin K-dependent proteins have various physiological roles that are not just restricted to coagulation and hemostasis. Although little is known of the functions of these proteins in direct tumorigenesis, they may contribute to remodeling of tumor microenvironment as vascular endothelial cell survival depends on vitamin K. In addition, the mRNA and protein expressions of *VKORC1L1* in lung have been reported.²⁰ The *VKORC1L1* gene is located on chromosome 7q11.21 and only contains three exons with 531 nucleotides. The encoded protein product has 176 amino acids (aa) with four endoplasmic reticulum transmembrane domains. In this case, exon 1 of *VKORC1L1* (aa 1–64) was fused with exons 20–29 (aa 1058–1620) of the *ALK* gene generating the final fusion protein which contains the full *ALK* tyrosine kinase domain (aa 1116–1329) (Figure 2). Interestingly, our patient's tumor was found to harbor *ALK* rearrangement in 2010, but the specific fusion partner could not be identified by fluorescence in situ hybridization at the time.

The other significance of this report is the demonstration of the sensitivity of the *ALK* T1151K resistance mutation to alectinib in a clinical patient case. The identification of T1151K as a resistance mutation to crizotinib was reported in 2011 by Zhang et al through an accelerated mutagenesis screen.²¹ Our group was the first to report this resistance mutation in an *ALK*-rearranged lung cancer patient with prior exposure to crizotinib and ceritinib. Based on co-crystal structures of ceritinib/*ALK*, alectinib/*ALK*, and lorlatinib/*ALK*, we concluded that T1151K confers resistance to ceritinib which may be rescued by alectinib or lorlatinib. We also speculated that brigatinib may not be able to completely overcome the T1151K/M resistance mutations according to an in vitro assay as well as the strong interaction of brigatinib with the P-loop of the *ALK* protein which may be interrupted by the T1151 mutation leading to drug resistance.²² The patient described in our previous case report has been on lorlatinib for over two years with a PR (–32% by RECIST 1.1). The dramatic response seen in this case would require longer follow-up to determine if the response is durable. Interestingly, as alectinib only has weak interaction with the P-loop of the *ALK* protein while lorlatinib has moderate interaction, alectinib may be more potent than lorlatinib to rescue patients with tumors harboring the *ALK* T1151K resistance mutation,

Figure 1 Contrast CT scans of the chest showing a left paravertebral mass at T1–2 level (indicated by a red circle) prior to use of alectinib (**A** and **C**) and resolution of this mass 14 weeks after initiating alectinib (**B** and **D**). Contrast CT scans of the chest showing decrease in size of the right pulmonary nodule (indicated by a red arrow) and significant improvement of the left lung aeration (indicated by a red star) 14 weeks after initiating alectinib (**F** and **H**) as compared with prior to use of alectinib (**E** and **G**). **Abbreviation:** CT, computed tomography.

which could explain a greater response seen in this patient treated with alectinib.

One limitation of this case report is that from a molecular standpoint it remains unclear how the ALK protein is activated by its fusion partner VKORC1L1 as this protein

product does not appear to contain a dimerization domain similar to EML4. It would be ideal to demonstrate positive ALK immunohistochemistry or the final VKORC1L1-ALK fusion protein and phospho-ALK by Western blot for instance. However, our patient declined tissue biopsy and

Table 1 Published fusion partners in *ALK*-rearranged lung cancer

Number	Fusion partner	Reference(s)
1	EML4	Soda et al, <i>Nature</i> 2007 ¹ ; Rikova et al, <i>Cell</i> 2007 ²
2	TFG	Rikova et al, <i>Cell</i> 2007 ²
3	KIF5B	Takeuchi et al, <i>Clin Cancer Res</i> 2009 ³
4	KCL1	Togashi et al, <i>PLoS One</i> 2012 ⁴
5	PTPN3	Jung et al, <i>Genes Chromosomes Cancer</i> 2012 ⁵
6	STRN	Majewski et al, <i>J Pathol</i> 2013 ⁶
7	HIP1	Fang et al, <i>J Thorac Oncol</i> 2014 ⁷ ; Hong et al, <i>J Thorac Oncol</i> 2014 ⁸
8	TPR	Choi et al, <i>J Thorac Oncol</i> 2014 ⁹
9	BIRC6	Shan et al, <i>J Thorac Oncol</i> 2015 ¹⁰
10	DCTN1	Iyevleva et al, <i>Cancer Lett</i> 2015 ¹¹
11	SQSTM1	Iyevleva et al, <i>Cancer Lett</i> 2015 ¹¹
12	SOCS5	Drilon et al, <i>Clin Cancer Res</i> 2015 ¹²
13	CLIP4	Drilon et al, <i>Clin Cancer Res</i> 2015 ¹²
14	CLTC	Ali et al, <i>Oncologist</i> 2016 ¹³
15	PRKARIA	Ali et al, <i>Oncologist</i> 2016 ¹³
16	PPM1B	Ali et al, <i>Oncologist</i> 2016 ¹³
17	EIF2AK3	Ali et al, <i>Oncologist</i> 2016 ¹³
18	CRIM1	Tan et al, <i>J Clin Oncol</i> 2016 ¹⁴
19	GCC2	Jiang et al, <i>Lung Cancer</i> 2018 ¹⁵
20	DYSF	Yin et al, <i>J Thorac Oncol</i> 2018 ¹⁶
21	ITGAV	Yin et al, <i>J Thorac Oncol</i> 2018 ¹⁶
22	VIT	Hu et al, <i>J Thorac Oncol</i> 2018 ¹⁷
23	PLEKHA7	Schrock et al, <i>J Thorac Oncol</i> 2018 ¹⁸
24	CUX1	Zhang et al, <i>J Thorac Oncol</i> 2018 ¹⁹
25	VKORC1L1	This case*

Notes: *This fusion partner was detected in conjunction with an acquired *ALK* resistance mutation.

Figure 2 Schema of the VKORC1L1-*ALK* fusion protein.

Notes: The *VKORC1L1* gene only contains three exons with 531 nucleotides. The encoded protein product has 176 aa with four endoplasmic reticulum transmembrane domains (aa 17–37, aa 92–112, aa 114–134, and aa 135–155). In this case, exon 1 of *VKORC1L1* (aa 1–64) is fused with exons 20–29 (aa 1058–1620) of the *ALK* gene generating the final fusion protein which contains the full *ALK* tyrosine kinase domain (aa 1116–1329). Of note, the luminal domain of the *VKORC1L1* protein itself contains aa 38–91, but the final VKORC1L1-*ALK* fusion protein only contains aa 38–64 which is highlighted in yellow. Similarly, the transmembrane domain of the *ALK* protein itself contains aa 1039–1059, but the final VKORC1L1-*ALK* fusion protein only contains aa 1058–1059 which is highlighted in brown.

Abbreviation: aa, amino acid.

his therapeutic bronchoscopy did not yield enough tissue to perform such laboratory assays. It is fortunate that liquid biopsy revealed this novel *ALK* fusion and an acquired *ALK* resistance mutation. More importantly, the dramatic response

seen in follow-up scans highly suggests that his disease process remains dependent on the *ALK* signaling pathway.

The patient will undergo routine CT scans to monitor treatment response as well as surveillance brain magnetic

resonance imaging as it is a common site of disease progression for patients with *ALK*-rearranged lung cancer. He does not have any brain metastasis at present. Should his disease progress again, we plan to explore resistance mechanism(s) by repeat biopsy. As patients are exposed to sequential *ALK* inhibitors, they are more likely to develop compound *ALK* resistance mutations. This phenomenon has been elegantly illustrated by Yoda et al in their approach to define lorlatinib-resistant *ALK* mutations.²³ To prevent highly refractory compound mutations from emerging, one might argue for the upfront use of the most potent *ALK* inhibitor and designing next-generation *ALK* inhibitors that can overcome these resistance mutations.

Conclusion

ALK-rearranged lung cancer defines a distinctive molecular cohort of patients whose outcomes are significantly improved by the availability of *ALK* inhibitors. Thus, screening for this driver mutation by a comprehensive molecular testing platform is absolutely necessary in routine practice. This is the first case report of a novel *VKORC1L1-ALK* fusion detected in a lung cancer patient. The patient had been on crizotinib for over 8 years until emergence of an *ALK* T1151K resistance mutation that was successfully treated with alectinib, demonstrating for the first time the activity of alectinib against T1151K in the clinic.

Disclosure

VWZ has received honoraria from Roche-Foundation Medicine, Roche/Genentech, Takeda, and Biocept, and consulting fees from TP Therapeutics. ABS and SMA are employees of Foundation Medicine, Inc., a wholly owned subsidiary of Roche. SIO has received honoraria from Pfizer, Roche-Foundation Medicine, Roche/Genentech, and Takeda, and has stock ownership in TP Therapeutics. The other authors report no conflicts of interest in this work.

References

- Soda M, Choi YL, Enomoto M, et al. Identification of the transforming *EML4-ALK* fusion gene in non-small-cell lung cancer. *Nature*. 2007;448(7153):561–566.
- Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell*. 2007;131(6):1190–1203.
- Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-*ALK*, a novel fusion onco-kinase identified by an immunohistochemistry-based diagnostic system for *ALK*-positive lung cancer. *Clin Cancer Res*. 2009;15(9):3143–3149.
- Togashi Y, Soda M, Sakata S, et al. KLC1-*ALK*: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. *PLoS One*. 2012;7(2):e31323.
- Jung Y, Kim P, Jung Y, et al. Discovery of *ALK-PTPN3* gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. *Genes Chromosomes Cancer*. 2012;51(6):590–597.
- Majewski JJ, Mittenpergher L, Davidson NM, et al. Identification of recurrent *FGFR3* fusion genes in lung cancer through kinome-centred RNA sequencing. *J Pathol*. 2013;230(3):270–276.
- Fang DD, Zhang B, Gu Q, et al. HIP1-*ALK*, a novel *ALK* fusion variant that responds to crizotinib. *J Thorac Oncol*. 2014;9(3):285–294.
- Hong M, Kim RN, Song JY, et al. HIP1-*ALK*, a novel fusion protein identified in lung adenocarcinoma. *J Thorac Oncol*. 2014;9(3):419–422.
- Choi YL, Lira ME, Hong M, et al. A novel fusion of TPR and *ALK* in lung adenocarcinoma. *J Thorac Oncol*. 2014;9(4):563–566.
- Shan L, Jiang P, Xu F, et al. BIRC6-*ALK*, a novel fusion gene in *ALK* break-apart FISH-negative lung adenocarcinoma, responds to crizotinib. *J Thorac Oncol*. 2015;10(6):e37–e39.
- Iyevleva AG, Raskin GA, Tiurin VI, et al. Novel *ALK* fusion partners in lung cancer. *Cancer Lett*. 2015;362(1):116–121.
- Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in “driver-negative” lung adenocarcinomas. *Clin Cancer Res*. 2015;21:3631–3639.
- Ali SM, Hensling T, Schrock AB, et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive *ALK*-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. *Oncologist*. 2016;21(6):762–770.
- Tan DS, Kim DW, Thomas M, et al. Genetic landscape of *ALK*+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1. *J Clin Oncol*. 2016;34(suppl; abstr 9064).
- Jiang J, Wu X, Tong X, et al. *GCC2-ALK* as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to *ALK* inhibitors. *Lung Cancer*. 2018;115:5–11.
- Yin J, Zhang Y, Zhang Y, Peng F, Lu Y. Reporting on two novel fusions, *DYSF-ALK* and *ITGAV-ALK*, coexisting in one patient with adenocarcinoma of lung, sensitive to crizotinib. *J Thorac Oncol*. 2018;13(3):e43–e45.
- Hu S, Li Q, Peng W, et al. *VIT-ALK*, a novel alectinib-sensitive fusion gene in lung adenocarcinoma. *J Thorac Oncol*. 2018;13(5):e72–e74.
- Schrock AB, Zhu VW, Hsieh WS, et al. Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors. *J Thorac Oncol*. 2018;13(9):1312–1323.
- Zhang M, Wang Q, Ding Y, et al. *CUX1-ALK*, a Novel *ALK* Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer. *J Thorac Oncol*. Epub 2018 Aug 7.
- Oldenburg J, Watzka M, Bevans CG. *VKORC1* and *VKORC1L1*: Why do Vertebrates Have Two Vitamin K 2,3-Epoxy Reductases? *Nutrients*. 2015;7(8):6250–6280.
- Zhang S, Wang F, Keats J, et al. Crizotinib-resistant mutants of *EML4-ALK* identified through an accelerated mutagenesis screen. *Chem Biol Drug Des*. 2011;78(6):999–1005.
- Zhu VW, Cui JJ, Fernandez-Rocha M, Schrock AB, Ali SM, Ou SI. Identification of a novel T1151K *ALK* mutation in a patient with *ALK*-rearranged NSCLC with prior exposure to crizotinib and ceritinib. *Lung Cancer*. 2017;110:32–34.
- Yoda S, Lin JJ, Lawrence MS, et al. Sequential *ALK* Inhibitors Can Select for Lorlatinib-Resistant Compound *ALK* Mutations in *ALK*-Positive Lung Cancer. *Cancer Discov*. 2018;8(6):714–729.

Lung Cancer: Targets and Therapy**Dovepress****Publish your work in this journal**

Lung Cancer: Targets and Therapy is an international, peer-reviewed, open access journal focusing on lung cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology, detection and screening; Cellular research and biomarkers; Identification of biotargets and agents with novel

mechanisms of action; Optimal clinical use of existing anticancer agents, including combination therapies; Radiation and surgery; Palliative care; Patient adherence, quality of life, satisfaction; Health economic evaluations. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/lung-cancer-targets--therapy-journal>